A randomized, double-blind, placebo-controlled, dose-escalation study of intravenous adult human mesenchymal stem cells (prochymal) after acute myocardial infarction.

By J. Hare, J. Traverse, T. Henry, N. Dib, R. Strumpf, S. Schulman, G. Gerstenblith, A. DeMaria, A. Denktas, R. Gammon and 4 more. Journal of the American College of Cardiology, 2009

1,334 citations recorded by the source corpus.

Subfields: Genetics, Molecular Biology, Surgery

View Paper: https://www.semanticscholar.org/paper/20c9d22b6729d1dfcdf9ef507e042c29e6366a3f

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Genetics

1. A. Keating
2. J. Karp

In Molecular Biology

1. A. Keating
2. J. Marshall

In Surgery

1. A. Keating
2. J. Karp

Citations in the corpus

• Safety of Cell Therapy with Mesenchymal Stromal Cells (SafeCell): A Systematic Review and Meta-Analysis of Clinical Trials (2012, background): “[17,18,26,27,29,31,33,35] Five studies explicitly reported and separated serious from non-serious adverse events; [13,14,20,24,46] two of these referenced a standardized approach to detailing adverse events developed by other organizations.”
• Stem Cell Therapies in Clinical Trials: Progress and Challenges. (2015, methodology): “Left ventricular ejection fraction was improved in patients given Prochymal MSCs when compared to placebo in a randomized, double blind, dose escalation study (Hare et al., 2009).”
• Mesenchymal stem cells are short-lived and do not migrate beyond the lungs after intravenous infusion (2012, methodology): “ORIGINAL RESEARCH ARTICLE published: 26 September 2012 doi: 10.3389/fimmu.2012.00297 Mesenchymal stem cells are short-lived and do not migrate beyond the lungs after intravenous infusion”
• Harnessing the Mesenchymal Stem Cell Secretome for the Treatment of Cardiovascular Disease (2012, methodology): “The first clinical trial for AMI using hMSCs was a randomized, double-blinded, placebo-controlled, dose-escalation study of allogenic hMSCs (Prochymal, Osiris Therapeutics, Inc., Baltimore,MD) (Hare et al., 2009).”
• Mesenchymal stromal cells: new directions. (2012, background): “MSCs are also highly activemetabolically, secreting not only components of the extracellular matrix (Wight et al., 1986) but also a vast array of cytokines (reviewed by Horwitz and Dominici, 2008).”
• Same or Not the Same? Comparison of Adipose Tissue-Derived Versus Bone Marrow-Derived Mesenchymal Stem and Stromal Cells (2012, neutral): “A randomized phase I clinical study assessing the systemic delivery of allogeneic BM-MSCs (Prochymal ) without immunosuppression after acute MI similarly showed significant improvements in symptomatic global assessments, cardiac arrhythmias, and pulmonary function in the MSC-treated groups relative ”